Intuitive Surgical Inc. Research & Ratings | ISRG
This article provides a detailed research and ratings overview for Intuitive Surgical Inc. (ISRG), including analyst ratings, price targets, stock grader information, company financials, and earnings estimates. It shows a consensus "Buy" rating with an average price target of $479.86 and details upcoming earnings reports.
Intuitive Surgical Inc. Stock Grades | ISRG
This article provides detailed stock information for Intuitive Surgical Inc. (ISRG), including its current stock grade, analyst ratings, key financial metrics, and company overview. It highlights an average price target of $479.86 from 35 ratings and notes the company's P/E Ratio (TTM) of 44.92. The company specializes in robotic-assisted surgical solutions.
What a competitive robotic surgery market means for providers
The article discusses the implications for healthcare providers as the robotic surgery market becomes more competitive, specifically mentioning Johnson & Johnson MedTech's Ottava system entering the field alongside Intuitive Surgical's da Vinci 5. It highlights the evolving landscape of medical devices and their impact on hospital strategies.
Are You Overpaying For Intuitive Surgical Stock Versus Its Rivals?
Intuitive Surgical (ISRG) boasts faster growth and higher operating margins than its peers but is also the most expensive when valued by its P/E ratio. Despite a recent stock dip, its earnings cost more than twice that of Globus Medical, its closest growth rival. Intuitive's revenue model relies heavily on recurring instrument sales post-system purchase, and while management forecasts continued procedure growth, a slowdown in the U.S. and the introduction of longer-lasting, lower-cost instruments could impact future revenue.
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?
This article compares Abbott Laboratories (ABT) and Intuitive Surgical (ISRG) as investment opportunities in 2026, weighing their respective strengths, financial performance, risk profiles, and valuations. While Abbott offers diversified stability across various healthcare segments, Intuitive Surgical provides high-growth potential in the specialized field of robotic-assisted surgery. The author ultimately recommends Intuitive Surgical due to its dominant market position and recurring revenue model.
Carlsmed Appoints Tony Jarc as Chief Product and AI Officer
Carlsmed, a medical technology company, has appointed Tony Jarc, Ph.D., as its new Chief Product and AI Officer. Dr. Jarc, formerly of Intuitive Surgical, will lead the development and commercialization of the company's next-generation technology platform and personalized spine surgery procedures. This strategic hire, along with recent executive appointments and enhanced CMS reimbursement, positions Carlsmed for accelerated growth in AI-enabled personalized spine surgery solutions.
Wall Street Zen downgrades Intuitive Surgical stock to Hold
Wall Street Zen has downgraded Intuitive Surgical stock from Buy to Hold, despite the company reporting an 18.40% increase in second-quarter revenue to USD 2.89 billion. The stock was trading at EUR 359.95 on October 1, 2026, slightly up from its prior close, but remains below its one-year high. Analysts show mixed sentiment, with a consensus target of USD 508.68, while JPMorgan recently cut its target to USD 450.00.
Carlsmed appoints Tony Jarc as chief product and AI officer
Carlsmed, Inc. has announced the appointment of Tony Jarc, Ph.D. as its Chief Product and AI Officer, a new position to oversee the company's technology platform and personalized spine surgery procedures. Dr. Jarc previously served as Vice President, Digital Products and Machine Learning Insights at Intuitive Surgical, Inc. This appointment follows other recent key hirings and coincides with enhanced CMS reimbursement for the company's aprevo lumbar fusion procedures.
Gilead Sciences, Inc. (GILD) stock price, news, quote and history
This article provides a comprehensive overview of Gilead Sciences, Inc. (GILD) stock, including its current price, recent news headlines, and performance data. It highlights the stock's trading activity, various news articles discussing its trends and comparisons with other healthcare stocks, and its trailing total returns against the S&P 500. The data indicates strong performance for GILD across different timeframes.
ADSEW - ADS-TEC ENERGY PLC Warrant stock news, filings & ratings
This article provides an overview of ADS-TEC ENERGY PLC Warrant (ADSEW), a B2B technology company specializing in intelligent battery buffered energy systems. It details the company's products, stock performance, recent SEC filings, and relevant news, highlighting its market position within the Industrial Specialties industry.
3 Reasons Johnson & Johnson Is Still a Buy With Its Stock Near a Record High
Johnson & Johnson (NYSE: JNJ) is presented as a strong buy opportunity despite its stock being near an all-time high, driven by its robust pharmaceutical pipeline, the potential of its Ottava robotic-assisted surgery system, and its reliable dividend program. The article highlights the company's ability to navigate competition with a diversified drug portfolio and continuous innovation, its expansion in the medtech sector, and its status as a Dividend King with 64 consecutive years of payout increases. These factors suggest continued growth and investor returns for the long term.
Move Over Tesla: Intuitive Surgical Shows Why Robotics Could Be Bigger Than Humanoids
While Tesla pursues general-purpose humanoid robots with its Optimus project, RoboStrategy, Inc. CEO Andrew Kang suggests that specializing in a single major labor market could lead to more substantial investment opportunities in robotics. He points to Intuitive Surgical as a prime example, having built a $145 billion market cap by dominating robotic-assisted surgery. This indicates that significant value can be created by robots that excel at a specific, large-scale task rather than trying to perform a wide range of human movements.
What You Need To Know Ahead of Intuitive Surgical's Earnings Release
Intuitive Surgical (ISRG) is set to release its Q3 2026 earnings, with analysts expecting an 8.7% increase in EPS to $2.13. Despite a recent 8.4% stock decline and a Q2 earnings miss that led to price target cuts due to lowered procedure growth guidance, analysts maintain a "Strong Buy" rating with an 18.5% upside. The company has consistently surpassed bottom-line estimates in the past four quarters.
Intuitive Surgical stock reports 18.50 percent Q2 revenue growth
Intuitive Surgical reported an 18.50 percent year-over-year revenue growth in Q2 2026, reaching USD 2.89 billion, and posted an adjusted EPS of USD 2.80, exceeding consensus estimates. The company's next earnings report is scheduled for October 20, 2026, with analysts anticipating continued double-digit revenue growth. The stock is currently trading above its yearly low, with a primary listing on NASDAQ.
Intuitive Surgical Inc (IUI1.HM) Analyst Insights, Price Targets & Recommendations
This article provides an overview of recent analyst ratings and recommendations for Intuitive Surgical Inc (IUI1.HM). It lists several upgrades, downgrades, and reiterations of ratings from various financial institutions between July and September 2026. The current stock price and performance are also shown.
Top Stock Reports for Visa, Intuitive Surgical & Williams Companies
This article features Zacks Investment Research's daily stock reports on 16 major companies, including Visa (V), Intuitive Surgical (ISRG), and The Williams Companies (WMB), along with micro-cap stocks Friedman Industries (FRD) and Jones Soda Co. (JSDA). Each report provides an analysis of the company's recent performance, growth drivers, and potential risks, culminating in a "Neutral" rating for Visa, Intuitive Surgical, and Williams Companies. The reports highlight key financial metrics and industry comparisons, offering investors insights into these companies' current market positions.
Top Stock Reports for Visa, Intuitive Surgical & Williams Companies
Zacks Research Daily has released new reports on 16 major stocks, including Visa Inc. (V), Intuitive Surgical, Inc. (ISRG), and The Williams Companies, Inc. (WMB), along with micro-caps Friedman Industries, Inc. (FRD) and Jones Soda Co. (JSDA). The reports provide in-depth analysis, highlighting company performance, growth opportunities, and potential risks, with a "Neutral" rating for Visa, Intuitive Surgical, and Williams Companies.
Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth
Fresenius Medical Care is refining its China commercial strategy to focus on long-term growth areas within the country's dialysis market. This involves prioritizing advanced in-center dialysis and critical-care technologies while streamlining existing portfolio elements. The company anticipates one-time costs of approximately €110 million in Q3 2026 due to the realignment, but expects no significant impact on future revenue outlook for its China Care Enablement business.
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
McKesson's stock is recommended for retention due to robust growth in specialty distribution, oncology services, and biopharma solutions, along with improving earnings and strong GLP-1 therapy distribution. Despite potential headwinds from branded drug price declines, generic conversions, and regulatory uncertainties, the company's strong first-quarter fiscal 2027 performance and raised EPS guidance underscore its positive momentum. McKesson's diversified growth drivers and operational efficiency position it well for sustained earnings, making it a viable hold for investors.
Medtronic (NYSE:MDT) Stock Price
This page provides an overview of Medtronic (NYSE:MDT) stock, including its current price performance, analyst consensus targets, and various user-submitted fair value narratives. It highlights recent news and updates, key financial details, and information about the company's segments and competitors. The stock is currently trading at US$89.50, with a fair value estimate of US$98.00, suggesting it is undervalued.
Intuitive Surgical price pierces price target - Forecast today - 29-09-2026
Intuitive Surgical (ISRG) has broken above its previous price target of $405.00, extending its gains. The stock's positive momentum is supported by an earlier breakout from a descending price channel and its position above the 50-day Simple Moving Average. Analysts maintain a bullish outlook, expecting the stock to target the $440.00 resistance level.
Texas Instruments price reaches price target - Forecast today - 29-09-2026
Texas Instruments (TXN) stock has reached its previous price target of $280.00 and is showing bullish technical formations, supported by trading above its 50-day Simple Moving Average. Despite some bearish signals from overbought momentum indicators, the outlook remains bullish, with a potential target of $300.00 if it breaks above $280.00.
Intuitive Surgical stock trades at EUR 364.65 before October 20 results
Intuitive Surgical (ISRG) stock is trading at EUR 364.65 on September 29, 2026, slightly down from its prior close, ahead of its Q3 earnings report on October 20, 2026. The company reported strong Q2 2026 revenue of USD 2.89 billion, up 18.40% year-over-year, with EPS exceeding consensus estimates, though procedure growth has moderated. Analysts largely maintain a "Buy" rating, with a consensus target of USD 508.68.
Intuitive Surgical, Inc. (ISRG) stock price, news, quote and history
This page provides an overview of Intuitive Surgical, Inc. (ISRG) stock, including its current price, recent news articles, and performance data. The stock is trading at $409.10, down 1.37%, with recent news focusing on its trending status, comparisons with other healthcare stocks, and approvals for its da Vinci SP system. The performance overview shows the stock's year-to-date return at -27.77% and a one-year return of -6.86%, significantly underperforming the S&P 500 benchmark.
Intuitive Surgical stock last trades at USD 414.55 on September 28, 2026
Intuitive Surgical stock closed at USD 414.55 on September 28, 2026, marking a 2.31 percent increase from its previous close. This rise follows the company's recent announcement regarding a meta-analysis published in Annals of Surgery Open, which highlighted favorable outcomes for da Vinci surgery, including shorter hospital stays and reduced conversion to open surgery compared to laparoscopic procedures.
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shareholders to Get $0.24 Quarterly Dividend
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) has declared a quarterly dividend of $0.24 per share, payable on October 30th to shareholders of record on September 30th. This represents an annualized dividend of $0.96 and a dividend yield of 1.1%, with a healthy payout ratio of 11.5%. The company also reported strong quarterly earnings, beating analyst expectations with $2.07 EPS and $2.18 billion in revenue.
Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward?
This article compares Gilead Sciences (GILD) and Abbott Laboratories (ABT) as dividend healthcare stocks, highlighting their differing risk-reward profiles. Gilead offers stronger current growth, particularly in its HIV franchise, but carries concentration risk and high R&D spending for diversification. Abbott, while growing slower, boasts a more diversified business across medical devices, diagnostics, and nutrition, along with a long history of consistent dividend increases.
Intuitive Surgical (ISRG) Down 30% This Year; Can Tonight’s Q2 Earnings Reverse the Bearish Channel?
Intuitive Surgical (ISRG) is down 30% year-to-date despite consistently beating earnings estimates, with analysts attributing the decline to valuation compression and tariff concerns rather than fundamental business issues. The company is set to announce its Q2 2026 earnings, with analysts expecting EPS of $2.48-$2.50 and revenue of $2.81-$2.82 billion. Key factors to watch in the earnings call include procedure volume growth, da Vinci 5 adoption rates, and any updates to full-year guidance, which could determine if the stock can break its current downtrend.
Can Medtronic’s (MDT) Core Units Keep Up With Management’s New Bets?
Medtronic (MDT) is focusing on accelerating growth through innovation platforms, strong core segments, and high-growth opportunities like robotic surgery and new devices. The company's recent collaboration with Cornerstone Robotics and a revised fiscal 2027 outlook signal a bullish future, with projected organic revenue growth of 7.25% to 7.75%. However, Medtronic faces intense competition from companies like Johnson & Johnson and Intuitive Surgical in these targeted growth markets, which could challenge its ability to capture significant market share.
Intuitive Surgical stock at USD 405.18 on September 25, 2026, up 1.42 percent
Intuitive Surgical (ISRG) stock closed at USD 405.18 on September 25, 2026, marking a 1.42 percent increase. This rise follows the company's announcement of a systematic review and meta-analysis of over 14 million da Vinci surgical procedures across 13 benign conditions. The analysis highlighted significant perioperative benefits of da Vinci surgery compared to laparoscopic and open surgeries, including reduced complications, shorter hospital stays, and quicker recovery times.
STAAR Surgical (STAA) Shares Skyrocket, What You Need To Know
STAAR Surgical (STAA) shares surged 6.3% after the company announced a new share repurchase program of up to $50 million over the next twelve months. This news is seen by investors as a sign that management believes the stock is undervalued. Despite this recent jump, the stock has been volatile, and a recent industry warning about insurance changes affecting procedure growth has caused broader sector concerns.
Intuitive expands push into cardiac market with CE mark
Intuitive's da Vinci 5 surgical robot has received CE mark approval for adult cardiac surgery in Europe, including coronary artery bypass procedures, marking a renewed focus on the cardiac market after decades of de-emphasizing it. The company aims to scale up minimally invasive cardiac surgery across Europe and has also secured FDA clearance for nine heart procedures in the U.S. This strategic expansion targets the significant market opportunity in cardiovascular disease treatment.
Intuitive expands push into cardiac market with CE mark
Intuitive's da Vinci 5 surgical robot has received CE mark approval for adult cardiac surgery in Europe, including coronary artery bypass procedures, marking the company's renewed focus on the cardiac market. This expansion comes as Intuitive aims to scale up minimally invasive cardiac surgery and follows a slowdown in U.S. procedure growth in the second quarter. The company is also enhancing its cardiac initiative in the U.S. with FDA clearance for nine heart procedures.
RVTY Launches New Kit in Europe for Newborn Type 1 Diabetes Detection
Revvity, Inc. (RVTY) has launched the GSP T1D 3plex kit in Europe, an automated solution for population-wide screening of newborns at risk for type 1 diabetes using dried blood spot samples. This kit is CE-IVDR-certified and aims to support early detection before symptoms appear, strengthening Revvity's diabetes portfolio. The company's stock saw a 6% gain following the announcement, reflecting positive investor response to this expansion into early T1D screening.
Intuitive Surgical stock heads into the open after a 0.3 percent gain
Intuitive Surgical (ISIN US46120E6023) stock gained 0.3 percent to USD 399.52 on September 24, 2026, slightly outperforming the Nasdaq Composite's less than 0.1 percent rise. This gain came despite a reported year-to-date decline of 29 percent for the stock. The article also mentions the company's Q2 2026 adjusted EPS of USD 2.80 and revenue of USD 2.89 billion.
Intuitive Surgical stock reports an earnings beat as revenue rises
Intuitive Surgical reported a Q2 2026 earnings beat, with adjusted EPS of USD 2.80 against an estimated USD 2.48, and revenue rising 18.4 percent year over year to USD 2.89 billion. The company also received a CE mark for its da Vinci SP system in European gynecologic procedures, expanding its market. Despite the strong performance, the stock remains significantly below its 52-week high, trading at USD 400.75 on September 24, 2026.
How AI Is Helping Match Patients to Clinical Trials Faster
This article discusses how AI is transforming clinical trial recruitment by streamlining patient identification, improving study design, and extracting insights from vast datasets. Pfizer's Vice President, Melinda Rottas, emphasizes that AI aids researchers in working more efficiently, reducing the time it takes to find eligible participants for trials, especially for conditions like oncology or rare diseases. The technology does not replace human decision-making but rather enhances researchers' ability to connect patients with suitable clinical trial opportunities, ultimately aiming to accelerate the development of life-changing treatments and expand access to underrepresented populations.
Here's Why You Should Retain Baxter Stock in Your Portfolio for Now
Baxter International (BAX) is undergoing a portfolio transformation, focusing on operational efficiency, connected-care growth, and strengthening high-growth businesses. While the company faces challenges like margin pressure from manufacturing costs, tariffs, and regulatory issues with Novum IQ, its large addressable markets and portfolio simplification initiatives support its long-term growth outlook. Shares of the Zacks Rank #3 (Hold) company have gained 23% year to date, outperforming the industry and the S&P 500 Index.
COO Unveils New Innovation Hub & Lens Launch Plans to Aid CooperVision
The Cooper Companies (COO) announced the opening of The Vision Centre, a new global innovation hub in Southampton, England, for its CooperVision business, focused on accelerating contact lens development and commercialization. The company also unveiled six product advancements, with launches planned over the next several years, aiming to drive future growth through enhanced innovation capabilities. Following the news, COO stock gained 1.4% at yesterday's close, despite a year-to-date decline, as these strategic investments are expected to strengthen its product portfolio and market position.
Here's Why You Should Retain Baxter Stock in Your Portfolio for Now
Baxter International (BAX) is undergoing a portfolio transformation, focusing on operational efficiency and growth in connected-care and advanced surgery businesses. While facing headwinds from manufacturing costs, tariffs, and regulatory issues with Novum IQ, the company benefits from large addressable markets and strategic simplification. Analysts project revenue growth for 2026 but a decrease in adjusted EPS, despite recent positive revisions.
Intuitive Surgical stock reports 18.5 percent Q2 revenue growth
Intuitive Surgical (ISRG) reported strong Q2 2026 revenue growth of 18.5 percent, reaching USD 2.89 billion, and surpassed analyst estimates by 2.6 percent. Despite this positive financial performance and improved operating margins, the stock closed 0.94 percent down on September 23, 2026, and remains 34.05 percent below its 52-week high, indicating investor focus on future growth drivers beyond just quarterly revenue. The company also highlighted clinical evidence supporting its da Vinci surgical system.
Intuitive Surgical Stock Has Plunged 29% This Year. Is the Market Overreacting?
Intuitive Surgical's stock has dropped 29% this year due to slowing procedure growth for its da Vinci robots, increased competition, and expiring ACA subsidies. Despite these headwinds, many analysts believe the sell-off is overdone, with a majority rating the stock as "buy" or "strong buy" and foreseeing significant upside due to long-term market potential and an aging demographic. Historically, similar declines have proven to be good buying opportunities for the medical device company.
Inspire Medical Systems, Inc. (INSP) latest stock news and headlines
This article provides the latest news and stock performance data for Inspire Medical Systems, Inc. (INSP). It highlights that the stock closed at $68.81 with a slight decrease and mentions several recent financial news articles and analyst recommendations. The performance overview shows that INSP has had negative trailing total returns year-to-date, 1-year, and 3-year periods, underperforming the S&P 500.
Intuitive Surgical vs. Stryker: Which MedTech Stock Is the Better Buy Now?
This article compares Intuitive Surgical (ISRG) and Stryker (SYK), two major players in the MedTech sector, evaluating which is the better investment. While Stryker offers diversified MedTech exposure and recovering capital-product momentum, Intuitive Surgical presents a more focused growth story with stronger operational momentum and a growing digital ecosystem. The article concludes that Intuitive Surgical is currently the more attractive bet due to its robotics leadership, recurring revenues, and expanding clinical applications, despite trading at a higher premium.
Intuitive Surgical vs. Stryker: Which MedTech Stock Is the Better Buy Now?
This article compares Intuitive Surgical (ISRG) and Stryker (SYK), two major MedTech companies specializing in robotic-assisted surgery, to determine which is a better buy. It highlights Intuitive Surgical's concentrated growth in its da Vinci, SP, and Ion systems, evidenced by strong procedure growth and recurring revenues, despite valuation premiums. Stryker, conversely, offers a diversified MedTech portfolio with a recovering Mako franchise and additional growth levers, trading at a discount. The article concludes that Intuitive Surgical's stronger operating momentum and expanding clinical applications make it the more attractive investment currently.
Telerobotic surgery is advancing around the world. Will the US embrace it?
Telerobotic surgery is rapidly advancing globally, with procedures already performed in various countries for conditions like stroke, heart disease, and cancer. While the technology promises to expand access to specialized care, particularly in underserved areas, its widespread adoption in the US faces hurdles including regulatory approvals, credentialing, licensing across states, and reimbursement models. Major medical device companies are investing in the technology, but challenges remain in building trust, ensuring network reliability, and integrating it into existing clinical workflows.
Intuitive Surgical, Inc. (ISRG) Options Chain - Yahoo Finance
This article provides the options chain for Intuitive Surgical, Inc. (ISRG) on Yahoo Finance. It indicates that there are currently no calls or puts available, with options data delayed by 15 minutes. The page also displays current stock information for ISRG, showing a price of 396.65 with a -1.35% change as of 1:49:36 p.m. EDT.
Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDx
Natera's Signatera test has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) as a companion diagnostic (CDx) for muscle-invasive bladder cancer (MIBC). This marks Natera's second PMDA authorization for Signatera in three months, with commercial launch in Japan expected in the first half of 2027. The approval is based on data from the IMvigor011 clinical trial and is anticipated to expand Signatera's adoption, enhancing Natera's presence in the precision oncology market, and driving its stock performance.
Minimally Invasive Robotic Surgical System Market Global Report 2026: Benchmark Intuitive Surgical, Johnson & Johnson, Medtronic, Stryker and Zimmer Biomet Now
The global minimally invasive robotic surgical system market is projected to reach $18.15 billion by 2030, growing from $8.9 billion in 2025 due to increased precision, patient outcomes, and adoption in outpatient facilities. Key growth drivers include improved reimbursement, precision medicine, and demand for minimally invasive procedures. Product innovation and strategic acquisitions by major players like Intuitive Surgical, Johnson & Johnson, and Medtronic are strengthening the market, with North America currently the largest regional market and Asia-Pacific expected to be the fastest-growing.
Intuitive Surgical stock gains on new da Vinci approvals
Intuitive Surgical's stock rose 6.5% on September 22, 2026, driven by new European approvals for its da Vinci surgical systems, expanding their potential use in transvaginal gynecologic procedures and adult cardiac surgery. The company also reported strong revenue growth, reaching $3.6 billion in the latest period, a 34% increase year-over-year. These developments link market reaction directly to the expanded indications rather than a separate earnings release, highlighting procedure growth and adoption as key operating variables.
